Alphatec Holdings, Inc. (NASDAQ:ATEC) Q2 2022 Results Conference Call August 4, 2022 4:30 PM ET
Company Participants
Pat Miles - Chairman & Chief Executive Officer
Todd Koning - Chief Financial Officer
Conference Call Participants
Eric Anderson - Cowen
Colin Clark - Stifel
Gibran Ahmed - Canaccord
Joseph Conway - Needham and Company
Phillip Dantoin - Piper Sandler
Operator
Good afternoon, everyone, and welcome to the webcast of ATEC's Second Quarter Financial Results. We would like to remind everyone that participants on the call will make forward-looking statements. These statements are based on current expectations and are subject to uncertainties that could cause actual results to differ materially.
These uncertainties are detailed in documents filed regularly with the SEC. During this call, you may hear the Company refer to reported amounts, which are in accordance with U.S. GAAP as well as non-GAAP or pro forma measures. Reconciliations of non-GAAP measures to U.S. GAAP can be found in the supplemental financial tables included in the press release, which identify and quantify all excluded items and provide management's view of why this information is useful to investors.
Leading today's call will be ATEC's Chairman and CEO, Pat Miles; and CFO, Todd Koning.
Now, I will turn the call over to Pat Miles. Please go ahead.
Pat Miles
Thanks, Audra, and welcome to the Q2 2022 financial results call. There will be some forward-looking statements. So if you review that at your leisure, we will be providing a forward view. So I'd say, a very good second quarter finished at a total revenue of $84 million for the quarter, which is a 35% year-over-year growth.
I would say that the procedural investment thesis is working. And so we're scaling top line growth toward positive adjusted EBITDA in 2023, training surgeons on PTP. There's a lot of them. There's big demand. We believe PTP is the next-generation lateral surgery. We're expanding indications with new product launches, reflecting our information-based competitive advantage in clinical publications, and we'll hit on that, extending EOS' influence while leveraging new hospital access. So we're getting more hospitals and more access.
And so we want to take a minute and just make sure that there's great clarity with regard to the procedural investment thesis. And so the way that we look at the world is we try to align with surgeons and surgeons don't think in terms of implants or widgets, since implants and widgets are the currency of the business, I think, oftentimes they are industry's priorities.